APA

Denys H., Martinez-Mena C. L., Martens M. T., D'Hondt R. G., Graas M. L., Evron E., Fried G., Ben-Baruch N. E., Vulsteke C. & Van Steenberghe M. M. (20210108). Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. : Breast cancer research and treatment.

Chicago

Denys Hannelore, Martinez-Mena Corina L, Martens Marc T, D'Hondt Randal G, Graas Marie-Pascale L, Evron Ella, Fried Georgeta, Ben-Baruch Noa E, Vulsteke Christof and Van Steenberghe Mona M. 20210108. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. : Breast cancer research and treatment.

Harvard

Denys H., Martinez-Mena C. L., Martens M. T., D'Hondt R. G., Graas M. L., Evron E., Fried G., Ben-Baruch N. E., Vulsteke C. and Van Steenberghe M. M. (20210108). Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. : Breast cancer research and treatment.

MLA

Denys Hannelore, Martinez-Mena Corina L, Martens Marc T, D'Hondt Randal G, Graas Marie-Pascale L, Evron Ella, Fried Georgeta, Ben-Baruch Noa E, Vulsteke Christof and Van Steenberghe Mona M. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer. : Breast cancer research and treatment. 20210108.